BioNexus Gene Lab Corp. (BGLC) P/E Ratio History
Deep ValueTrading at -2.7x · 0th percentile of 5-year range · Significant discount to historical valuation · Data 2021–2022
Loading P/E history...
P/E Ratio Analysis
As of June 22, 2026, BioNexus Gene Lab Corp. (BGLC) trades at a price-to-earnings ratio of -2.7x, with a stock price of $2.42 and trailing twelve-month earnings per share of $-1.28.
The current P/E is 100% below its 5-year average of 6588.3x. Over the past five years, BGLC's P/E has ranged from a low of 4197.6x to a high of 10913.4x, placing the current valuation at the 0th percentile of its historical range.
Compared to the Healthcare sector median P/E of 22.1x, BGLC trades at a 112% discount to its sector peers. The sector includes 233 companies with P/E ratios ranging from 0.0x to 194.5x.
Relative to the broader market, BGLC trades at a notable discount to the S&P 500 median P/E of 24.3x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our BGLC DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
BGLC Cross-Benchmark Valuation
How does the current P/E compare to sector peers and the broader market?
BGLC P/E vs Peers
Molecular and Genetic Diagnostics peers sorted by market cap
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $43B | 41.7 | 3.01Best | +23%Best | |
| $172B | 26.2Lowest | 12.40 | +7% |
Lower P/E can signal a discount or weaker growth expectations; PEG adds growth context.
BGLC Historical P/E Data (2021–2022)
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Period End | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2022 Q2 | - | $136.90 | $0.02 | 7360.2x | +12% |
| FY2022 Q1 | - | $205.30 | $0.03 | 6798.0x | +3% |
| FY2021 Q4 | Dec 31 2021 | $255.70 | $0.05 | 4852.0x | -26% |
| FY2021 Q3 | - | $141.70 | $0.03 | 5408.4x | -18% |
| FY2021 Q2 | Jun 30 2021 | $138.10 | $0.03 | 4197.6x | -36% |
| FY2021 Q1 | Mar 31 2021 | $252.10 | $0.02 | 10913.4x | +66% |
Average P/E for displayed period: 6588.3x
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
5+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
BGLC — Frequently Asked Questions
Quick answers to the most common questions about buying BGLC stock.
What is BGLC's P/E ratio?
BioNexus Gene Lab Corp. (BGLC) trailing twelve-month P/E ratio is -2.7x, based on TTM diluted EPS of $-1.28. The 5-year average P/E is 6588.3x and the historical range spans 4197.6x to 10913.4x.
Is BGLC stock overvalued or undervalued?
BGLC trades at -2.7x P/E, below its 5-year average of 6588.3x. At the 0th percentile of its historical range (4197.6x–10913.4x), the stock is priced at a discount to its own history.
Is BGLC stock expensive?
No, BGLC is not expensive on a historical basis. The current P/E of -2.7x is below the 5-year average of 6588.3x and sits at the 0th percentile of its valuation range.
What is BGLC's historical P/E range?
Over the past 5 years, BGLC's P/E ratio has ranged from 4197.6x to 10913.4x, with a median of 6798.0x and an average of 6588.3x. The current P/E of -2.7x places the stock at the 0th percentile of this range. Full historical data spans 2021–2022.
How does BGLC's P/E compare to the S&P 500?
BGLC trades at -2.7x P/E versus the S&P 500 median of 24.3x. The 111% discount to the market suggests lower growth expectations or perceived higher risk.
How does BGLC's valuation compare to Healthcare peers?
BioNexus Gene Lab Corp. P/E of -2.7x compares to the Healthcare sector median of 22.1x. The discount suggests lower growth expectations, weaker margins, or higher perceived risk relative to peers. See the peer comparison table on this page for ticker-by-ticker P/E and PEG.
What is BGLC's PEG ratio?
BGLC PEG ratio is N/A, based on a P/E of -2.7x and EPS growth of 41.2%. PEG normalises P/E by growth and helps compare stocks with different earnings trajectories.
What is BGLC's earnings yield?
BGLC earnings yield is N/A, the inverse of its -2.7x P/E ratio. Earnings yield represents the percentage of each dollar invested that the company earns. It can be compared directly to bond yields to assess relative attractiveness of stocks versus fixed income.